Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Joseph Pantginis reaffirmed a Buy rating on Adlai Nortye with a $20 price target, citing the strategic advancement of its AN9025 dual-arm clinical strategy. The intermittent weekly dosing arm, supported by preclinical data showing sustained tumor control, aims to improve the therapeutic window and manage toxicity. This approach addresses class-wide safety constraints of pan-RAS inhibitors, reinforcing confidence in the company's pipeline and long-term value.
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Adlai Nortye Ltd. Sponsored ADR, with a price target of $20.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Joseph Pantginis has given his Buy rating due to a combination of factors, notably the strategic advancement of AN9025 into an intermittent weekly dosing arm alongside the ongoing daily regimen. He views this dual-arm Phase 1 design as expanding the program’s opportunities, while the unchanged $20 price target reflects confidence that this broader clinical approach can enhance the asset’s long-term value.
Pantginis highlights that the weekly schedule is grounded in preclinical data showing sustained tumor control even during drug holidays, supporting a hypothesis of improved therapeutic window and manageable toxicity. He also underscores that Adlai Nortye is tackling the class-wide safety constraints of pan-RAS(ON) inhibitors through both innovative scheduling with AN9025 and targeted delivery via its RASiCA-based ADC AN4035, reinforcing his constructive outlook on the company’s pipeline and risk-reward profile.